Publication:
Pulmonologists' Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey.

dc.contributor.authorMiravitlles, Marc
dc.contributor.authorGonzález-Torralba, Fernando
dc.contributor.authorRepresas-Represas, Cristina
dc.contributor.authorPomares, Xavier
dc.contributor.authorMárquez-Martín, Eduardo
dc.contributor.authorGonzález, Cruz
dc.contributor.authorAmado, Carlos
dc.contributor.authorForné, Carles
dc.contributor.authorAlonso, Soledad
dc.contributor.authorAlcázar, Bernardino
dc.contributor.authorBarrecheguren, Miriam
dc.contributor.authorJurado Mirete, Juan María
dc.contributor.authorNaval, Elsa
dc.date.accessioned2023-05-03T13:37:24Z
dc.date.available2023-05-03T13:37:24Z
dc.date.issued2022-07-12
dc.description.abstractIdentifying the variables that guide decision-making in relation to the use of inhaled corticosteroids (ICS) can contribute to the appropriate use of these drugs. The objective of this study was to identify the clinical variables that physicians consider most relevant for prescribing or withdrawing ICS in COPD. A cross-sectional survey was conducted in Spain from November 2020 to May 2021. Therapeutic decisions on the use of ICS in 11 hypothetical COPD patient profiles were collected using an online survey answered by specialists with experience in the management of patients with COPD. Mixed-effects logistic regression was used to analyze the impact of patients' characteristics in the therapeutic decision for prescribing ICS or proceeding to its withdrawal. A total of 74 pulmonologists agreed to collaborate in the survey and answered the questionnaire. The results showed great variability, with only 2 profiles achieving consensus for starting or withdrawing the treatment. The frequency and severity of exacerbations influenced the decision to prescribe ICS in a dose-response fashion (1 exacerbation odds ratio (OR) = 1.86, 95% confidence interval (CI) 1.02 to 3.43, two exacerbations OR = 11.6, 95% CI: 4.47 to 30.2 and three OR = 123, 95% CI: 25 to 601). Similarly, increasing blood eosinophils and history of asthma were associated with ICS use. On the other hand, pneumonia reduced the probability of initiating treatment with ICS (OR = 0.54 [0.29 to 0.98]). Lung function and dyspnea degree did not influence the clinician's therapeutic decision. The results for withdrawal of ICS were similar but in the opposite direction. In accordance with guidelines, exacerbations, blood eosinophils and history of asthma or pneumonia are the factors considered by pulmonologist for the indication or withdrawal of ICS. However, the agreement in prescription or withdrawal of ICS when confronted with hypothetical cases is very low, suggesting a great variability in clinical practice.
dc.identifier.doi10.2147/COPD.S369118
dc.identifier.essn1178-2005
dc.identifier.pmcPMC9288191
dc.identifier.pmid35855745
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288191/pdf
dc.identifier.unpaywallURLhttps://www.dovepress.com/getfile.php?fileID=82096
dc.identifier.urihttp://hdl.handle.net/10668/20458
dc.journal.titleInternational journal of chronic obstructive pulmonary disease
dc.journal.titleabbreviationInt J Chron Obstruct Pulmon Dis
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number1577-1587
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectCOPD
dc.subjectbronchodilators
dc.subjecteosinophils
dc.subjectexacerbation
dc.subjectinhaled corticosteroids
dc.subjectwithdrawal
dc.subject.meshAdministration, Inhalation
dc.subject.meshAdrenal Cortex Hormones
dc.subject.meshAsthma
dc.subject.meshBronchodilator Agents
dc.subject.meshCross-Sectional Studies
dc.subject.meshHumans
dc.subject.meshPneumonia
dc.subject.meshPulmonary Disease, Chronic Obstructive
dc.subject.meshPulmonologists
dc.subject.meshSpain
dc.titlePulmonologists' Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number17
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9288191.pdf
Size:
4.14 MB
Format:
Adobe Portable Document Format